Consistent with previous reports, ensartinib showed high clinical efficacy. Longitudinal ctDNA analysis
could be a powerful tool in predicting treatment outcomes and revealing resistant mechanisms of
ensartinib. We observed G1269A, G1202R and E1210K as the major resistant mutations to ensartinib. READ ARTICLE
Cancer Research DOI:10.1158/1538-7445.AM2020-2997
Authors: Yunpeng Yang, Jie Huang, Tao Wang, Jianya Zhou, Jing Zheng, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Li Mao, Giovanni Selvaggi, Larry Zhu, Shanshan Xiao, Li Zhang